ADDITIVE SOLUTION FORMULA 3 AS-3 0.410 G / 100 ML
SODIUM CHLORIDE : 0.410 G / 100 ML SODIUM CITRATE DIHYDRATE : 0.588 G / 100 ML CITRIC ACID MONOHYDRATE : 0.042 G / 100 ML SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE : 0.276 G / 100 ML ADENINE : 0.030 G / 100 ML DEXTROSE : 1.10 G / 100 ML · DIN 02324393 · TERUMO BCT, INC.
Health Canada status: DORMANT
What is ADDITIVE SOLUTION FORMULA 3 AS-3?
ADDITIVE SOLUTION FORMULA 3 AS-3 0.410 G / 100 ML contains SODIUM CHLORIDE : 0.410 G / 100 ML SODIUM CITRATE DIHYDRATE : 0.588 G / 100 ML CITRIC ACID MONOHYDRATE : 0.042 G / 100 ML SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE : 0.276 G / 100 ML ADENINE : 0.030 G / 100 ML DEXTROSE : 1.10 G / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 02324393, held by TERUMO BCT, INC., supplied as SOLUTION for 0-UNASSIGNED administration. Health Canada currently lists it as dormant, status dated 15-Sep-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02324393 |
|---|---|
| Brand name | ADDITIVE SOLUTION FORMULA 3 AS-3 |
| Generic / active ingredient | SODIUM CHLORIDE : 0.410 G / 100 ML SODIUM CITRATE DIHYDRATE : 0.588 G / 100 ML CITRIC ACID MONOHYDRATE : 0.042 G / 100 ML SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE : 0.276 G / 100 ML ADENINE : 0.030 G / 100 ML DEXTROSE : 1.10 G / 100 ML |
| Manufacturer | TERUMO BCT, INC. |
| Strength | 0.410 G / 100 ML |
| Dosage form | SOLUTION |
| Route of administration | 0-UNASSIGNED |
| Schedule | Ethical |
| ATC code | V07AC BLOOD TRANSFUSION, AUXILIARY PRODUCTS |
| AHFS class | 20:12.04.92 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 15-Sep-2025 |
| Original market date | 2013-05-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code V07AC BLOOD TRANSFUSION, AUXILIARY PRODUCTS. 12 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| 12% SODIUM CHLORDIE PROCESSING SOLUTION | 12 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00783625 |
| ADDITIVE SOLUTION SODIUM ADENINE GLUCOSE MANNITOL (SAGM) | 8.77 G | SOLUTION | MACO PHARMA | MARKETED | DIN 02444097 |
| ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) FORMULA A | 2.45 G / 100 ML | SOLUTION | FRESENIUS KABI AG | MARKETED | DIN 00788139 |
| ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) FORMULA A | 2.45 G / 100 ML | SOLUTION | TERUMO BCT, INC. | MARKETED | DIN 02469731 |
| ANTICOAGULANT SOD CITRATE SOLTN 4GM/100ML | 4 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00060313 |
| ANTICOAGULANT SODIUM CITRATE 4% W/V SOLUTION, USP | 4 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02377411 |
| ANTICOAGULANT SODIUM CITRATE SOLUTION, USP | 4 G / 100 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02529637 |
| ANTICOAGULANT SOLUTION CITRATE PHOSPHATE DEXTROSE (CPD) | 25.5 G | SOLUTION | MACO PHARMA | MARKETED | DIN 02444100 |
| DEXTROSE 0.2% AND 0.9% SOD CHLOR SOLUTION | 900 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00783641 |
| GLYCEROLYTE 57 SOLUTION | 30 MG / 100 ML | SOLUTION | FRESENIUS KABI AG | MARKETED | DIN 00783668 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.